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See Article, pages 1283–1292Bacterial translocation (BT) includes themigrationof viablemicro-
organisms but also all microbial products (endotoxins such as
lipopolysaccharide [LPS], lipoteichoic acid, bacterial DNA, peptido-
glycans, and fragments, e.g. muramyldipeptide, etc.) across an
even, anatomically intact intestinal barrier from the intestinal
lumen tomesenteric lymph nodes (MLN) and other extraintestinal
organs and sites [2]. Although the term ‘‘BT’’ summarizes all these
various bacterial products, the route, and site as well as the immu-
nological response between themaremost likely very different. BT
in liver disease has been extensively studied in the past, mainly
due to its long known role as an underlying mechanism in the
development of spontaneous bacterial infections such as sponta-
neous bacterial peritonitis (SBP) in decompensated cirrhosis
[17]. Moreover, in advanced cirrhosis, pathological BT most likely
impacts on the natural course of liver cirrhosis via triggering and/
or aggravatinghepatic failure, encephalopathy or hepatorenal syn-
drome. On this background, it has been proposed that intestinal
decontamination could improve disease severity in cirrhotic
patients [7]. Concerning the mechanisms promoting BT in chronic
liver disease, the majority of the studies have been performed in
decompensated cirrhosis unraveling threemain factors: intestinal
bacterial overgrowth (IBO), increased intestinal permeability (IP),
and impaired immunity. IBO has usually been evaluated at only
one site, namely the upper small intestine, by applying culture
techniques since it is deﬁned as >105 CFU/ml aspirate. However,
it needs to be stressed that only a minority of the enteral ﬂora
can be cultured by conventional techniques andwhether the small
intestine is the site of most prevalent translocation has not been
addressed so far. Nonetheless, in advanced liver cirrhosis IBO is a
very frequent ﬁnding and has been linked to the development of
BT, endotoxemia, and SBP [1,12]. Indeed, bacteria causing SBP
are not only normal commensal gut bacteria but most frequently
exactly those overgrowing in the small intestine. So it has been
said that BT is caused by ‘‘too much of the good guys at the wrong
place’’ since, the upper intestine is not made to host this load of
bacteria. Increases in IP in cirrhosis have been reported by variousJournal of Hepatology 20
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tive stress, and alterations in enterocyte mitochondrial function
[17]. Moreover, the secretory barrier limiting adhesion of bacteria
to the epithelium is diminished due to deﬁciencies in bile, IgA, and
antimicrobial peptides [6,9,16].
More recently, BT has been recognized as crucial event also in
non-decompensated and non-cirrhotic stages of liver disease
being particularly relevant for the progression of liver disease,
i.e. ﬁbrogenesis [5,14], inﬂammation [15], and –possibly– can-
cerogenesis [19]. However, so far the mechanisms leading to
pathological BT in these early phases of liver disease have not
been addressed. In this issue of the Journal of Hepatology, Fouts
et al. applied (i) DNA pyrosequencing techniques enabling differ-
entiated characterization of the intestinal microbiome; (ii) an
intestinal loop model for evaluation of intestinal permeability
in various segments along the intestinal tract (iii) at various time-
points during the early course of two different animal models of
liver injury [4]. BT occured independently of any microbial
changes both quantitative and qualitative in bile-duct-ligated
(BDL) rats and preceded the occurrence of bacterial overgrowth
in CCl4-induced liver injury. Moreover, increased intestinal per-
meability throughout the intestine (except for proximal small
bowel) was observed as early as one day following liver injury
in both models and was associated with an early increase of sys-
temic LPS levels as well as the number of viable bacteria in MLN.
This provocative original investigation sheds light on the
sequence of events after acute liver injury culminating in BT.
Indeed, these data in conjunction with previous data by the same
group [18] underscore the primary role of barrier failure indepen-
dent from any alteration in intestinal ﬂora, easing the access of
bacteria and bacterial products from the gut to the circulation
in liver injury. It cannot be assumed that observations made in
cirrhotic conditions are transferable to the scenario of early liver
disease. In fact, advanced cirrhosis is characterized by marked
hemodynamic, metabolic, and immunological alterations second-
ary to liver failure and portal hypertension, that are absent in
early stages of the disease. Therefore, unraveling the mechanisms
causing the intestinal barrier to fail in early phases of liver injury
seems of upmost relevance for the ‘‘hepatologist’’ of the future,
expanding the focus clearly beyond the liver towards the gut
and its habitants.12 vol. 56 j 1221–1223
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In agreement with the essential role of occludin for intestinal
integrity and tight junction function, Fouts et al. observed
decreased expression of occludin in both animal models [4].
However, most tantalizing is the fact that occludin is downregu-
lated at different sites with reduced expression in colon and small
intestine in BDL- and CCl4-mice, respectively. However, increases
in IP were observed also at sites with normal occludin expression
emphasizing the complexity of IP regulation. Indeed, occludin
represents only one out of more than 50 tight junction proteins
and TJ-function is not only a matter of protein expression. Intes-
tinal integrity and permeability are known to involve Rho GTPas-
es, myosin light chain kinase, and various non-epithelial cell
types such as intraepithelial lymphocytes [10].
Likewise, highly interesting in Fouts et al. investigation is the
ﬁnding that LPS levels did not decrease despite a greater than 90%
reduction of intestinal ﬂora by treatment of mice with non-
absorbable antibiotics [4]. This may hint to the vast importance
of mucosa-adherent vs. luminal (free) bacteria. The former is
clearly the site of major interest since it is potentially less acces-
sible for antibiotic treatment but via attachment to the epithe-
lium and transcytosis is the one that is translocating. In that
regard, it still remains to be clariﬁed why only a real minority
of bacterial species translocate to MLN in liver disease. Also these
new data by Fouts et al. again ﬁnd Enterobacteriaceae among the
most frequent species translocating. This translocation occurs
independently of the LPS/TLR4 signaling pathway in BDL rats.
However, commensal bacteria are composed of a number of
molecular structures activating multiple TLRs and besides TLRs
other pattern-recognition receptors (PRR) such as membrane-
bound C-type lectin receptors or NOD-like-receptors play a cen-
tral role in the initiation of immune response to translocating
bacteria [8]. Most likely, various PRRs in concert orchestrate this
scenario and thus, delineating the relative contribution of each of
these PRRs will represent the ‘‘Gordian knot’’ to elucidate the
phenomenon of pathological BT in liver disease.
The study by Fouts et al. also clearly expands our understand-
ing of how different models of liver disease impact on the gut
microbiome by showing that BDL within days led to bacterial
overgrowth of aerobic and anaerobic germs in the small and large
intestine whereas in CCl4-induced liver injury quantitative
changes of intestinal bacteria occurred only after 8 weeks of
treatment when ﬁbrosis had already developed. The bacterial
spectrum (namely microbial species richness and evenness)
remained unaltered in BDL but a dysbiosis was observed in
CCl4-treated mice. This dysbiosis reﬂects an increased number
of operational taxonomic units within the phylum Firmicutes,
(e.g. Lactobacillus) and Actinobacteria along with a marked reduc-
tion in microbial diversity. Reduced microbial diversity has also
been observed in cirrhotic patients [3], and otherwise has been
associated with obesity and inﬂammatory bowel disease [11].
Finally, pyrosequencing analyses in animals treated with CCl4,
alcohol feeding, BDL or a genetic fatty liver model, revealed that
the enteric microbiome differs with respect to the etiology of
liver disease and shares only some operational taxonomic units.
Thus, it appears not conclusive that a unique microbial species
is of crucial relevance for progression of liver disease indepen-
dent of its etiology.
However, a number of intriguing questions remain. First, is it
liver injury per se that disrupts the homeostasis of the gut micro-
biota or is the causative agent (e.g. alcohol, CCl4) or stimulus (e.g.
diet) or missing bile acids (e.g. in BDL) causing the composition1222 Journal of Hepatology 2012and density of the intestinal ﬂora to change? Utilizing pure intra-
hepatic models of liver injury such as viral hepatitis should pro-
vide insight into this question. Second, what measures are most
suited to lower inﬂow of LPS (and other bacterial products and/
or bacteria) in liver disease? This ‘‘billion dollar question’’ mainly
relates to potential detrimental side effects known to be associ-
ated with long-term use of antibiotics and underlines the need
for a more detailed understanding of the host-microbial homeo-
stasis at the intestinal mucosal surface during liver disease.
Indeed, recent data in HBV and HCV patients indicate that host
factors (e.g. intestinal integrity and host response to bacterial
products) are more important than changes of the microbiome
for the progression of liver disease [13]. Thus, improving barrier
function and limiting the host response to BT may be the key
to success.
At the end it may clearly be important to know ‘‘who lives’’
and ‘‘at which site’’ in the intestinal tract of an individual at risk
for or with ongoing liver injury. Advancing our knowledge of the
gut microbiome and of the mechanisms altering intestinal barrier
function in early stages of liver injury and disease will help to
more accurately target this ‘‘Achilles heel in liver disease’’ and
therefore, will guide the development of novel therapeutic and
particularly preventive strategies.Conﬂict of interest
The authors declare that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.
References
[1] Bauer TM, Schwacha H, Steinbruckner B, Brinkmann FE, Ditzen AK, Aponte JJ,
et al. Small intestinal bacterial overgrowth in human cirrhosis is associated
with systemic endotoxemia. Am J Gastroenterol 2002;97 (9):2364–2370.
[2] Berg RD, Garlington AW. Translocation of certain indigenous bacteria from
the gastrointestinal tract to the mesenteric lymph nodes and other organs in
a gnotobiotic mouse model. Infect Immun 1979;23 (2):403–411.
[3] Chen Y, Yang F, Lu H, Wang B, Lei D, Wang Y, et al. Characterization of fecal
microbial communities in patients with liver cirrhosis. Hepatology 2011;54
(2):562–572.
[4] Fouts DE, Torralba M, Nelson KE, Brenner DA, Schnabl B. Bacterial
translocation and changes in the intestinal microbiome in mouse models
of liver disease. J Hepatol 2012;56:1283–1292.
[5] Gabele E, Dostert K, Hofmann C, Wiest R, Scholmerich J, Hellerbrand C, et al.
DSS induced colitis increases portal LPS levels and enhances hepatic
inﬂammation and ﬁbrogenesis in experimental NASH. J Hepatol 2011;55
(6):1391–1399.
[6] Kadaoui KA, Corthesy B. Secretory IgA mediates bacterial translocation to
dendritic cells in mouse Peyer’s patches with restriction to mucosal
compartment. J Immunol 2007;179 (11):7751–7757.
[7] Kalambokis GN, Tsianos EV. Rifaximin reduces endotoxemia and improves
liver function and disease severity in patients with decompensated cirrhosis.
Hepatology 2012;55 (2):655–656.
[8] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate
receptors in infection and immunity. Immunity 2011;34 (5):637–650.
[9] Lorenzo-Zuniga V, Bartoli R, Planas R, Hofmann AF, Vinado B, Hagey LR, et al.
Oral bile acids reduce bacterial overgrowth, bacterial translocation, and
endotoxemia in cirrhotic rats. Hepatology 2003;37 (3):551–557.
[10] Marchiando AM, Graham WV, Turner JR. Epithelial barriers in homeostasis
and disease. Annu Rev Pathol 2010;5:119–144.
[11] Nagalingam NA, Lynch SV. Role of the microbiota in inﬂammatory bowel
diseases. Inﬂamm Bowel Dis 2011.
[12] Pardo A, Bartoli R, Lorenzo-Zuniga V, Planas R, Vinado B, Riba J, et al. Effect of
cisapride on intestinal bacterial overgrowth and bacterial translocation in
cirrhosis. Hepatology 2000;31 (4):858–863.vol. 56 j 1221–1223
JOURNAL OF HEPATOLOGY
[13] Sandler NG, Koh C, Roque A, Eccleston JL, Siegel RB, Demino M, et al. Host
response to translocated microbial products predicts outcomes of patients
with HBV or HCV infection. Gastroenterology 2011;141 (4):1220–1230,
1230 e1221–1223.
[14] Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, et al.
TLR4 enhances TGF-beta signaling and hepatic ﬁbrosis. Nat Med 2007;13
(11):1324–1332.
[15] Seki E, Schnabl B. Role of innate immunity and the microbiota in liver
ﬁbrosis: crosstalk between the liver and gut. J Physiol 2012;590 (Pt
3):447–458.
[16] Teltschik Z, Wiest R, Beisner J, Nuding S, Hofmann C, Schoelmerich J, et al.
Intestinal bacterial translocation in rats with cirrhosis is related to compro-Journal of Hepatology 2012mised paneth cell antimicrobial host defense. Hepatology 2011; http://
dx.doi.org/10.1002/hep.24789 [Epub ahead of print].
[17] Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology
2005;41 (3):422–433.
[18] Yan AW, Fouts DE, Brandl J, Starkel P, Torralba M, Schott E, et al. Enteric
dysbiosis associated with a mouse model of alcoholic liver disease.
Hepatology 2011;53 (1):96–105.
[19] Yu LX, Yan HX, Liu Q, Yang W, Wu HP, Dong W, et al. Endotoxin
accumulation prevents carcinogen-induced apoptosis and promotes liver
tumorigenesis in rodents. Hepatology 2010;52 (4):1322–1333.vol. 56 j 1221–1223 1223
